Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Pia Burman; Britt Edén-Engström; Bertil Ekman; F Anders Karlsson; Erik Schwarcz; Jeanette Wahlberg

doi:10.1530/EJE-15-0807

Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Pia Burman, Britt Edén-Engström, Bertil Ekman, F Anders Karlsson, Erik Schwarcz, Jeanette Wahlberg

Translational Muscle Research

Research output: Contribution to journal › Article › peer-review

Abstract

The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

Original language	English
Pages (from-to)	17-24
Journal	European Journal of Endocrinology
Volume	174
Issue number	1
DOIs	https://doi.org/10.1530/EJE-15-0807
Publication status	Published - 2016

Subject classification (UKÄ)

Endocrinology and Diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/EJE-15-0807

http://www.ncbi.nlm.nih.gov/pubmed/26582653?dopt=Abstract

Cite this

@article{a4fbd21b71b6470b9c5ceefc99a67e32,

title = "Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.",

abstract = "The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.",

author = "Pia Burman and Britt Ed{\'e}n-Engstr{\"o}m and Bertil Ekman and Karlsson, {F Anders} and Erik Schwarcz and Jeanette Wahlberg",

year = "2016",

doi = "10.1530/EJE-15-0807",

language = "English",

volume = "174",

pages = "17--24",

journal = "European Journal of Endocrinology",

issn = "1479-683X",

publisher = "Society of the European Journal of Endocrinology",

number = "1",

}

TY - JOUR

T1 - Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

AU - Burman, Pia

AU - Edén-Engström, Britt

AU - Ekman, Bertil

AU - Karlsson, F Anders

AU - Schwarcz, Erik

AU - Wahlberg, Jeanette

PY - 2016

Y1 - 2016

N2 - The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

AB - The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

U2 - 10.1530/EJE-15-0807

DO - 10.1530/EJE-15-0807

M3 - Article

C2 - 26582653

SN - 1479-683X

VL - 174

SP - 17

EP - 24

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 1

ER -

Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this